Order is mission critical: this reagent is required to perform all testing which provide healthcare providers with critical information in the detection/management of allergic reactions for SAN…
Ended Awarded
- Contract number
- HT009025FG0830039
- Awardee
-
Phadia US Inc. UEI DK4EVCWUNUM4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $49,920
Award facts
- Contract value 100% obligated
- $49,920.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Portage, MI 49002, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a mission-critical contract to Phadia US Inc.'s Immunodiagnostics Division on August 1, 2025, valued at $49,920.38 through a Blanket Purchase Agreement (BPA) call. This firm-fixed-price order procures specialized allergy testing reagents required to support healthcare providers across San Antonio military treatment facilities and other Department of Defense medical installations. The reagents are essential for the detection and management of allergic reactions, representing a critical component of the Defense Health Agency's diagnostic capabilities at military medical facilities nationwide. No set-aside designation was utilized for this procurement, indicating an open market competitive award.
Phadia US Inc., a foreign-owned subsidiary of Thermo Fisher Scientific, is a recognized specialized provider of immunodiagnostic equipment, analyzers, and reagents to federal defense and veterans' healthcare agencies. The contract extends through September 30, 2025, and will be performed at the company's facility in Portage, Michigan. This award represents an incremental purchase order under Phadia's existing BPA relationships with the Defense Health Agency and demonstrates the company's established role as a key supplier of immunological testing solutions for military medical operations. The company also maintains significant Indefinite Delivery/Indefinite Quantity contract vehicles with the Air Force valued at $13.8 million each, supporting procurement of IMMUNOCAP system analyzers and related allergy diagnostic equipment across Air Force medical facilities.
Description
Order is mission critical: this reagent is required to perform all testing which provide healthcare providers with critical information in the detection/management of allergic reactions for SAN antonio market and other military treatment facilities.
Quick answers
Who was awarded contract HT009025FG0830039?
HT009025FG0830039 was awarded to Phadia US Inc. by Defense Health Agency (Department of Defense) on August 1, 2025.
How much is contract HT009025FG0830039 worth?
The government has obligated $49,920 on HT009025FG0830039.
Is contract HT009025FG0830039 an order under another contract?
Yes. HT009025FG0830039 is a BPA call under FA301624A0046, a blanket purchase agreement.
Was contract HT009025FG0830039 competed?
The extent of competition for HT009025FG0830039 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award